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INTRODUCTION
It is estimated that about 529,828 women are di-
agnosed with cervical cancer globally, of which
275,128 died due to this condition.1,2 Approxi-
mately 85 % of those cases occur in developing
countries. Based on World Health Statistics in
2010, the incidence of cervical cancer in Indonesia
was 100 per 100,000 people with approximately
200,000 new cases diagnosed annually. About 70%
of cervical cancer cases were already at an advan-
ced stage upon diagnosis.2,3
In 2007, 3,112 cases of cervical cancer were re-
ported, contributing to 75% of all gynecologic can-
cer cases. Based on the cancer staging, it was found
that among all the cases 439 were at stage I
(14.1%); 1,104 cases were at stage II (35.4%);
1,392 cases were at stage III (44.7%) and 117 cases
were at stage IV (5,7%). Five year survival rate for
stage I, II, III and IV were 50%, 40%, 20% and 0%,
respectively.4
Cervical cancer is a condition that could poten-
tially be prevented.5 However, due to the lack of
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Objective: To evaluate the "false negative" of VIA in our study popu-
lation compared to HPV DNA test as the reference test or gold stan-
dard.
Method: We processed the cervical swab from 1,279 patients with
negative VIA and detected the HPV DNA by using INNO-Lipa HPV
DNA test.
Result: From 1,279 women with negative VIA, 65 samples were ex-
cluded because of incomplete data and duplicate examination. From
the remaining 1,214 women with negative VIA, 39 samples were
confirmed to be positive for HPV DNA by both PCR and hybridiza-
tion, leading to a "false negative" result of 3.21%.
Conclusion: This study shows VIA as a very effective method for
cervical cancer screening. VIA gives an excellent result, particularly
for ectocervix, with minimal cost. Therefore, it is very suitable to be
used as cervical cancer screening in developing countries like In-
donesia.
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Abstrak
Tujuan: Untuk mengevaluasi "negatif palsu" IVA dibandingkan de-
ngan tes DNA HPV sebagai pemeriksaan standar referensi dan baku
emas.
Metode: Terdapat 1.279 subjek dengan IVA negatif yang memenuhi
kriteria inklusi. Hasil negatif tersebut dibandingkan dengan pemerik-
saan baku yaitu tes DNA HPV INNO-Lipa.
Hasil: Dari 1.279 pasien dengan IVA negatif, sebanyak 65 sampel
dieksklusi karena data yang tidak lengkap dan pemeriksaan duplikat. Di
antara 1.214 sampel yang tersisa, ditemukan 39 sampel positif setelah
dibandingkan dengan tes DNA HPV baik PCR maupun hibridisasi. Ber-
dasarkan temuan ini, didapatkan hasil negatif palsu IVA sebanyak
3,21%.
Kesimpulan: Studi ini menunjukkan bahwa IVA merupakan metode
skrining yang sangat efektif. Dengan biaya yang minimal, IVA mem-
berikan hasil yang sangat baik pada fase skrining terutama untuk ek-
toserviks. IVA sangat sesuai diterapkan sebagai metode skrining kan-
ker serviks di negara-negara berkembang seperti Indonesia.
[Maj Obstet Ginekol Indones 2014; 4: 216-219]
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effective screening methods, preventive measures
are difficult to carry out. Several methods are re-
cognized for early detection of the disease. One of
them is Pap test, which is a cytology test consid-
ered to be effective as a screening method. None-
theless, the cost of this test is considered high and
requires trained medical personnel to perform the
test. Another detection method is HPV DNA testing.
It is considered superior to other methods, as it can
detect pre-cancerous lesions 30%-100% more ac-
curately compared to Pap test. However, this is not
a cost effective test making it inappropriate as a
screening method.6 Another method that can de-
tect cervical cancer in its early stage is visual in-
spection with acetic acid (VIA). This is a low cost
test and is easy to perform in settings with limited
health facilities. This test is a simple test with a
sensitivity and specificity comparable to Pap test.
Therefore, VIA is appropriate to be used in Indo-
nesia for cervical cancer screening.
Various controversies exist on the ability of VIA
method as an effective method that can be widely
applied in Indonesia. If a large proportion of sub-
jects with negative VIA turned out to have HPV in-
fection, then VIA method may not be appropriate
for cervical cancer screening. In order to achieve
the target of an ideal screening coverage rate of
80%, it would require a screening method that is
simple with low cost, but has a high accuracy. In
this study, we evaluated VIA accuracy by involving
a large number of subjects among the population
of Jakarta, Indonesia. The aim of this study is to
provide a strong rationalization for recommending
VIA as a standard method of screening in Indone-
sia, which can subsequently be used as a national
program.
METHODS
This study is a cross sectional study. It was con-
ducted from January 2012 to May 2013 at the obs-
tetrics and gynecology clinic in Dr. Cipto Mangun-
kusumo hospital, primary health centers, and other
health facilities that are included in the "See and
Treat" Female Cancer Programme (FCP) in Jakarta
as well as at the Department of Gynecology and
Department of Pathology, Leids Universitair Me-
disch Centrum (LUMC), The Netherlands. We in-
cluded subjects who agreed to participate in this
study, married, aged 20-50 years, resides perma-
nently in Jakarta and had negative result from VIA
test. In total, 1,279 subjects were suitable for in-
clusion into the study. We processed the cervical
swab of all subjects and detected the HPV DNA by
using PCR and electrophoresis test by INNO-Lipa.
RESULTS
Our youngest subject was aged 31 years old and
the oldest was 50 years old, with a mean age of
40.9 years old. The first marriage is considered as
the first sexual contact, which was relatively young,
just a little over 20 years old. Based on marital
status, most of our subjects were married once
(88.2%). Considering the partners’ marital status,
almost all were married once (92.6%). Almost all
subjects did not smoke (94.3%). Based on the base-
line characteristics, the subjects in this study had
a low risk for HPV infection. Characteristic of sub-
jects are shown in Table 1.
Table 1. Baseline Characteristics
Variable Description
Age (years) 40.9   9.28
Age at first marriage (years) 22.0   4.31
Marital status
 Married once 1054 (88.2%)
 Married more than once 75 (6.3%)
 Widow 65 (5.5%)
Marital status of partner
 Married once 1060 (92.6%)
 Married more than once 84 (7.4%)
Parity 2.3   1.57
Smoking habit
 Smoke 69 (5.7%)
 Do not smoke 1145 (94.3%)
Table 2. HPV DNA Test Results
Variable n %
HPV DNA (+) 39 3.21
HPV DNA (-) 1175 96.79
HR-HPV 13 68.42
Non HR-HPV 5 26.32
HPV-X 1 5.26
Single infection 22 56.41
Multiple infection 17 43.59
HR-HPV = high-risk HPV
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The prevalence of HPV infection in subjects with
negative VIA obtained in this study was 3.21%, which
was very low compared to other studies on the
prevalence of HPV in the screened population. If the
HPV DNA test is used as a reference standard, this
percentage can be considered as "false negative".
HPV DNA test results are presented in table 2.
DISCUSSION
The prevalence of HPV infection obtained from this
study is relatively low at 3.21% compared to the
prevalence of HPV infection acquired from pre-
vious studies that have been conducted in asymp-
tomatic reproductive age female population rang-
ing from 5%-40%.7
Existing studies suggest that the majority of
sexually active women will have HPV infection
throughout their life, of which 75% will be infected
by more than one type of HPV.8 Clifford et al re-
ported the proportion of HPV infection in cytologi-
cally normal women aged 15-74 years from 11
countries (Nigeria, India, Vietnam, Thailand, Korea,
Colombia, Argentina, Chile, The Netherlands, Italy,
and Spain). The range of HPV infection in cytologi-
cally normal women was reported to range bet-
ween 1.4% in Spain to 25.6% in Nigeria.9 Molano
et al10 reported the prevalence of HPV in 1,859
subjects with normal cytology was 14.8%, while
Bennani et al11 reported a very high rate, which
was 42.5%. HPV prevalence in cytologically normal
women in Honduras as reported by Tabora et al
was even as high as 51%.12 Compared to these
studies, the 3.21% found in our study is relatively
low, allowing us to conclude that VIA can provide
results comparable to or maybe even better than
cytology. Bellinson et al in a study of 1,997 women
in China concluded that the sensitivity of VIA is
equal to or better than conventional cytology.13
From research conducted by Vet et al in the pe-
riod of October 2004-February 2006 in Indonesia
to 2,686 women aged 15-70 years in Jakarta, Ta-
sikmalaya, and Bali, the overall prevalence of HPV
was 11.4%. This figure is higher than that obtained
from this study, because of the different popula-
tion. Our study was done on subjects who had prior
screening (VIA negative), while Vet et al conducted
research in the general population who has not
been screened.14 In another study conducted in the
United States on a sample of 1,921 women aged
14-59 years, the overall prevalence of HPV was
26.8%.15
CONCLUSION
The prevalence of HPV infection in VIA negative
women in this study was 3.21%. Based on our
study results, we support VIA as a very effective
method for cervical cancer screening. VIA provides
excellent results with minimal cost. Therefore, it is
very suitable to be used for cervical cancer screen-
ing in developing countries like Indonesia with the
aim of eventually decreasing the incidence of cer-
vical cancer.
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